Cue Biopharma Earns $7.5M Preclinical Milestone from Boehringer Ingelheim
Cue Biopharma has secured a $7.5 million preclinical milestone payment under its collaboration with Boehringer Ingelheim following selection and approval of its first compound for lead optimization, CUE-501. The agreement also contemplates up to $337.5 million in additional research, development and commercial milestones plus royalties.
1. Milestone Achievement and Payment
Cue Biopharma has achieved a preclinical milestone with Boehringer Ingelheim through the selection and approval of its first compound for lead optimization, CUE-501, triggering a $7.5 million payment expected in May 2026.
2. Collaboration Agreement and Upside Potential
Under the multi-year collaboration, Cue Biopharma is eligible to receive up to $337.5 million in additional research, development and commercial milestone payments, as well as royalty payments on future net sales.
3. Pipeline Implications
The collaboration leverages Cue’s Immuno-STAT® platform to develop bispecific molecules for autoimmune and inflammatory diseases, complementing the company’s lead asset, CUE-401, as it advances toward clinical testing.